Bruno Quesnel

List of Publications by Year
in descending order

250	12,049	31902	30848
papers	citations	53 h-index	102 g-index

255	255	255	13022
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pairing cells of different sizes in a microfluidic device for immunological synapse monitoring. Lab on A Chip, 2022, 22, 908-920.	3.1	3
2	Put in a â€œCa2+llâ€•to Acute Myeloid Leukemia. Cells, 2022, 11, 543.	1.8	3
3	TRPC3 shapes the ER-mitochondria Ca2+ transfer characterizing tumour-promoting senescence. Nature Communications, 2022, 13, 956.	5.8	29
4	Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology, 2022, 101, 1321-1331.	0.8	4
5	Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction. European Journal of Medicinal Chemistry, 2022, 236, 114343.	2.6	11
6	p65/RelA NFâ€ºB fragments generated by RIPK3 activity regulate tumorigenicity, cell metabolism, and stemness characteristics. Journal of Cellular Biochemistry, 2022, 123, 543-556.	1.2	3
7	Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity. PLoS ONE, 2022, 17, e0267508.	1.1	0
8	Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure. International Journal of Molecular Sciences, 2022, 23, 5555.	1.8	5
9	Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents. Leukemia Research, 2022, 118, 106871.	0.4	0
10	Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors. Cancers, 2022, 14, 3368.	1.7	7
11	Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy. EJHaem, 2021, 2, 196-210.	0.4	1
12	Systemic Pulmonary Events Associated with Myelodysplastic Syndromes: A Retrospective Multicentre Study. Journal of Clinical Medicine, 2021, 10, 1162.	1.0	3
13	Acute Myeloid Leukemia: Is It T Time?. Cancers, 2021, 13, 2385.	1.7	8
14	Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des MyÃ©lodysplasies (GFM). Journal of Clinical Oncology, 2021, 39, 1575-1583.	0.8	169
15	Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers, 2021, 13, 3034.	1.7	56
16	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer Medicine, 2021, 10, 6336-6343.	1.3	6
17	Expanded Access Program: Evaluating Safety of Erythrocytes Encapsulating L-Asparaginase in Combination with Polychemotherapy in Patients Under 55 Years Old with Acute Lymphoblastic Leukaemia (ALL) at Risk to Receive Other Formulations of Asparaginase. Blood, 2021, 138, 1214-1214.	0.6	2
18	Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood, 2021, 138, 246-246.	0.6	21

#	Article	IF	Citations
19	ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Molecular Metabolism, 2021, 55, 101410.	3.0	3
20	Modulation of the Gal-9/TIM-3 Immune Checkpoint with Î±-Lactose. Does Anomery of Lactose Matter?. Cancers, 2021, 13, 6365.	1.7	7
21	Clinically Relevant Oxygraphic Assay to Assess Mitochondrial Energy Metabolism in Acute Myeloid Leukemia Patients. Cancers, 2021, 13, 6353.	1.7	3
22	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	13.9	335
23	Familial myeloid malignancies with germline TET2 mutation. Leukemia, 2020, 34, 1450-1453.	3.3	36
24	Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19. Cancers, 2020, 12, 1992.	1.7	24
25	Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size. Leukemia Research Reports, 2020, 13, 100202.	0.2	6
26	Aggressiveness Potential of Spontaneous Canine Mucosal Melanoma Can Dictate Distinct Cancer Stem Cell Compartment Behaviors in Regard to Their Initial Size and Expansion Abilities. Stem Cells and Development, 2020, 29, 919-928.	1.1	5
27	Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer, 2020, 2, zcaa002.	1.6	142
28	Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia. Leukemia, 2020, 34, 2230-2233.	3.3	1
29	Measurement of Protein-Protein Interactions through Microscale Thermophoresis (MST). Bio-protocol, 2020, 10, e3574.	0.2	10
30	Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort. International Journal of Antimicrobial Agents, 2019, 53, 781-788.	1.1	18
31	CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Medicine, 2019, 8, 1279-1288.	1.3	27
32	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. Blood, 2019, 134, 2414-2416.	0.6	14
33	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Advances, 2019, 3, 4238-4251.	2.5	72
34	Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hautsâ€deâ€France AML observatory. American Journal of Hematology, 2019, 94, E24-E27.	2.0	5
35	APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des MyÃ©lodysplasies (GFM). Blood, 2019, 134, 677-677.	0.6	62
36	MYC Overexpressing Multiple Myeloma Are Dependent on GLS1. Blood, 2019, 134, 853-853.	0.6	0

#	Article	IF	Citations
37	Targeting MYC in multiple myeloma. Leukemia, 2018, 32, 1295-1306.	3.3	89
38	Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. Cell Death and Disease, 2018, 9, 325.	2.7	71
39	Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. Journal of Visualized Experiments, 2018, , .	0.2	7
40	CAR T-cells: A John von Neumann legacy?. Current Research in Translational Medicine, 2018, 66, 35-36.	1.2	13
41	Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology. BMC Cancer, 2018, 18, 1219.	1.1	11
42	Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Frontiers in Oncology, 2018, 8, 665.	1.3	47
43	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 1-1.	0.6	57
44	A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial. Blood, 2018, 132, 467-467.	0.6	9
45	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplantation, 2017, 52, 539-543.	1.3	30
46	Metabolic rewiring in cancer cells overexpressing the glucocorticoid-induced leucine zipper protein (GILZ): Activation of mitochondrial oxidative phosphorylation and sensitization to oxidative cell death induced by mitochondrial targeted drugs. International Journal of Biochemistry and Cell Biology, 2017, 85, 166-174.	1.2	10
47	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. European Respiratory Journal, 2017, 49, 1700178.	3.1	9
48	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	5.8	53
49	Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. Blood, 2017, 130, 832-835.	0.6	55
50	Sub-clonal analysis of the murine C1498 acute myeloid leukaemia cell line reveals genomic and immunogenic diversity. Immunology Letters, 2017, 192, 27-34.	1.1	1
51	TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2017, 23, 6325-6335.	3.2	64
52	Long-term follow up of invasive aspergillosis in allogeneic stem cell transplantation recipients and leukemia patients: Differences in risk factors and outcomes. Current Research in Translational Medicine, 2017, 65, 77-81.	1.2	7
53	Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia, 2017, 31, 555-564.	3.3	34
54	PD-1/PD-L1 binding studies using microscale thermophoresis. Scientific Reports, 2017, 7, 17623.	1.6	56

#	Article	IF	Citations
55	Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial. Blood, 2017, 130, 889-889.	0.6	25
56	Role of IRF4 in resistance to immunomodulatory (IMid) compoundsÂ® in WaldenstrÃ¶mâ€™s macroglobulinemia. Oncotarget, 2017, 8, 112917-112927.	0.8	5
57	BACH2 promotes indolent clinical presentation in WaldenstrÃ¶m macroglobulinemia. Oncotarget, 2017, 8, 57451-57459.	0.8	2
58	GILZ overexpression attenuates endoplasmic reticulum stress-mediated cell death via the activation of mitochondrial oxidative phosphorylation. Biochemical and Biophysical Research Communications, 2016, 478, 513-520.	1.0	16
59	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature Communications, 2016, 7, 10767.	5.8	177
60	Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells. Scientific Reports, 2016, 6, 30405.	1.6	25
61	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematology,the, 2016, 3, e186-e195.	2.2	359
62	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia, 2016, 30, 1416-1418.	3.3	16
63	Genomic Landscape of CXCR4 Mutations in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2016, 22, 1480-1488.	3.2	102
64	Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. Clinical Pharmacokinetics, 2016, 55, 397-405.	1.6	72
65	De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory. Blood, 2016, 128, 4013-4013.	0.6	4
66	Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. Oncotarget, 2016, 7, 62377-62385.	0.8	20
67	Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors. Oncotarget, 2016, 7, 39473-39485.	0.8	58
68	Monocyte chemoattractant protein 1 (MCPâ€1/CCL2) contributes to thymus atrophy in acute myeloid leukemia. European Journal of Immunology, 2015, 45, 396-406.	1.6	21
69	B7â€H3 protein expression in acute myeloid leukemia. Cancer Medicine, 2015, 4, 1879-1883.	1.3	32
70	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood, 2015, 125, 3618-3626.	0.6	197
71	Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research, 2015, 39, 501-504.	0.4	46
72	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leukemia Research, 2015, 39, 1443-1447.	0.4	9

#	Article	IF	Citations
73	CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy. Cancer Research, 2015, 75, 3902-3911.	0.4	36
74	Expanded Access Program of Graspa for Treatment of Patients with Acute Lymphoblastic Leukemia Unable to Receive Other Form of L-Asparaginase - a Status Update (NCT02197650). Blood, 2015, 126, 4877-4877.	0.6	1
75	IDH1/2but notDNMT3Amutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 2015, 6, 42345-42353.	0.8	92
76	Abstract 3216: Immunogenicity and genomic profiling reveal sub-clonal diversity of a murine acute myeloid leukemia (AML) cell line. , 2015, , .		0
77	Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group. Blood, 2015, 126, 2568-2568.	0.6	0
78	RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. Cell Death and Disease, 2014, 5, e1384-e1384.	2.7	105
79	5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. European Journal of Cancer, 2014, 50, 196.	1.3	12
80	Outcomes in <scp>RBC</scp> transfusionâ€dependent patients with <scp>L</scp>owâ€/<scp>I</scp>ntermediateâ€1â€risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the <scp>MDS</scp>â€004 study. European Journal of Haematology, 2014, 93, 429-438.	1.1	32
81	<scp>MYD</scp>88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. British Journal of Haematology, 2014, 167, 506-513.	1.2	71
82	Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. American Journal of Hematology, 2014, 89, 410-416.	2.0	91
83	Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. Cancer Research, 2014, 74, CT231-CT231.	0.4	23
84	Multiclonal Diagnosis and MRD Follow-up in ALL with HTS Coupled with a Bioinformatic Analysis. Blood, 2014, 124, 1083-1083.	0.6	1
85	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia. Blood, 2014, 124, 117-117.	0.6	27
86	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. Blood, 2014, 124, 2327-2327.	0.6	1
87	Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA). Blood, 2014, 124, 482-482.	0.6	2
88	Abstract 1342: RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. , 2014, , .		0
89	Epidemiology of Adults AML in Nord-Pas De Calais and Picardy. Blood, 2014, 124, 2281-2281.	0.6	0
90	Monitoring of Wilmsâ€™ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1265-1265.	0.6	0

#	Article	IF	Citations
91	Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group. Blood, 2014, 124, 1062-1062.	0.6	12
92	Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leukemia Research, 2013, 37, 637-640.	0.4	45
93	Tumor Dormancy: Long-Term Survival in a Hostile Environment. Advances in Experimental Medicine and Biology, 2013, 734, 181-200.	0.8	12
94	Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leukemia Research, 2013, 37, 573-579.	0.4	29
95	Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older. Journal of Clinical Oncology, 2013, 31, 321-327.	0.8	68
96	Longâ€term followâ€up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. American Journal of Hematology, 2013, 88, 556-559.	2.0	30
97	The PI3K/AKT Signaling Pathway Controls the Quiescence of the Low-Rhodamine123-Retention Cell Compartment Enriched for Melanoma Stem Cell Activity. Stem Cells, 2013, 31, 641-651.	1.4	57
98	Outcome of older patients with acute myeloid leukemia in first relapse. American Journal of Hematology, 2013, 88, 758-764.	2.0	49
99	Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. American Journal of Hematology, 2013, 88, 948-954.	2.0	45
100	Administration of alemtuzumab and <scp>G</scp>â€<scp>CSF</scp> to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase <scp>II</scp> study. European Journal of Haematology, 2013, 91, 315-321.	1.1	28
101	MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood, 2013, 121, 4504-4511.	0.6	214
102	Linezolid induces ring sideroblasts. Haematologica, 2013, 98, e138-e140.	1.7	21
103	The B7-H3 Protein In Acute Myeloid Leukemia. Blood, 2013, 122, 2620-2620.	0.6	1
104	Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML). Blood, 2013, 122, 2796-2796.	0.6	4
105	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APLâ€“ Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. Blood, 2013, 122, 495-495.	0.6	0
106	Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study. Blood, 2013, 122, 2753-2753.	0.6	0
107	AML At First Relapse: A Real Life Picture. Blood, 2013, 122, 3895-3895.	0.6	0
108	Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leukemia and Lymphoma, 2012, 53, 1068-1076.	0.6	50

#	Article	IF	Citations
109	GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells. Oncogene, 2012, 31, 1419-1430.	2.6	40
110	Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. Blood, 2012, 119, 6172-6173.	0.6	33
111	The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood, 2012, 120, 5084-5085.	0.6	50
112	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leukemia Research, 2012, 36, 1112-1118.	0.4	9
113	Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. Leukemia Research, 2012, 36, 1330-1333.	0.4	9
114	Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. British Journal of Haematology, 2012, 157, 764-766.	1.2	49
115	MYD88 L265P Mutation in Waldenstrom's Macroglogulinemia. Blood, 2012, 120, 1307-1307.	0.6	2
116	Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM). Blood, 2012, 120, 297-297.	0.6	2
117	Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. Blood, 2012, 120, 422-422.	0.6	3
118	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. Blood, 2012, 120, 1697-1697.	0.6	0
119	B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenstroˆm Macroglobulinemia. Blood, 2012, 120, 1288-1288.	0.6	0
120	Metabolites of Tryptophan Catabolism Are Elevated in Sera of Patients with Myelodysplastic Syndromes and Inhibit Hematopoietic Progenitor Amplification. Blood, 2012, 120, 3843-3843.	0.6	0
121	Exploiting Mitochondrial Dysfunction for Effective Elimination of Imatinib-Resistant Leukemic Cells. PLoS ONE, 2011, 6, e21924.	1.1	49
122	Repression of the RHOH gene by JunD. Biochemical Journal, 2011, 437, 75-88.	1.7	8
123	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 2011, 118, 3765-3776.	0.6	424
124	Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood, 2011, 117, 403-411.	0.6	348
125	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood, 2011, 118, 1754-1762.	0.6	52
126	Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia, 2011, 25, 1207-1209.	3.3	35

#	Article	IF	Citations
127	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 2011, 25, 1147-1152.	3.3	430
128	Synthesis and biological evaluation of phenstatin metabolites. Bioorganic and Medicinal Chemistry, 2011, 19, 6042-6054.	1.4	28
129	A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors. Molecular Cancer, 2011, 10, 105.	7.9	9
130	Expression of CD34 in hematopoietic cancer cell lines reflects tightly regulated stem/progenitorâ€like state. Journal of Cellular Biochemistry, 2011, 112, 1277-1285.	1.2	14
131	Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. Leukemia Research, 2011, 35, 448-458.	0.4	17
132	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. Journal of Clinical Oncology, 2011, 29, 3322-3327.	0.8	421
133	Acute Myocarditis Induced by Hypomethylating Agents. Journal of Clinical Oncology, 2011, 29, e411-e412.	0.8	12
134	Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. Blood, 2011, 118, 972-972.	0.6	1
135	Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA). Blood, 2011, 118, 253-253.	0.6	1
136	Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. Blood, 2010, 115, 78-88.	0.6	44
137	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica, 2010, 95, 892-899.	1.7	18
138	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 2010, 116, 1132-1135.	0.6	121
139	In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunology, Immunotherapy, 2010, 59, 1839-1849.	2.0	143
140	A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients. Experimental Hematology, 2010, 38, 124-131.e4.	0.2	34
141	Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response. Gene Therapy, 2010, 17, 880-891.	2.3	19
142	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia, 2010, 24, 1094-1096.	3.3	225
143	Dormance tumorale: quiescence ouÂÃ©quilibre?. Hematologie, 2010, 16, 355-362.	0.0	0
144	Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with lowâ€“intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. Leukemia and Lymphoma, 2010, 51, 1668-1677.	0.6	2

#	Article	IF	Citations
145	Activity of Ladanein on Leukemia Cell Lines and Its Occurrence inMarrubium vulgare. Planta Medica, 2010, 76, 86-87.	0.7	27
146	Humulane and Germacrane Sesquiterpenes from Ferula lycia. Journal of Natural Products, 2010, 73, 780-783.	1.5	10
147	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2010, 28, 3717-3723.	0.8	189
148	Antifungal and Cytotoxic Activity of Withanolides from Acnistus arborescens. Journal of Natural Products, 2010, 73, 1313-1317.	1.5	24
149	Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood, 2010, 116, 3735-3742.	0.6	141
150	Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA). Blood, 2010, 116, 2183-2183.	0.6	13
151	FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes. Blood, 2010, 116, 232-232.	0.6	3
152	Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML. Blood, 2010, 116, 3997-3997.	0.6	3
153	Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS. Blood, 2010, 116, 439-439.	0.6	10
154	Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group. Blood, 2010, 116, 505-505.	0.6	3
155	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. Blood, 2010, 116, 2171-2171.	0.6	0
156	AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM). Blood, 2010, 116, 2911-2911.	0.6	0
157	Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. Blood, 2010, 116, 4171-4171.	0.6	0
158	A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial. Blood, 2010, 116, 3996-3996.	0.6	0
159	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 2009, 94, 1676-1681.	1.7	234
160	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. Journal of Clinical Oncology, 2009, 27, 4747-4753.	0.8	123
161	Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leukemia Research, 2009, 33, 547-550.	0.4	18
162	Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patientsâ€™ sera by HPLC and is inducible by IFN-Î³. Leukemia Research, 2009, 33, 490-494.	0.4	91

#	Article	IF	Citations
163	Methyltransferases in myelodysplastic syndromes: Guilty or not guilty?. Leukemia Research, 2009, 33, 601-602.	0.4	2
164	Tissue Factor Pathway Inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis, 2009, 204, e4-e14.	0.4	40
165	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291.	0.6	264
166	Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.. Blood, 2009, 114, 1054-1054.	0.6	5
167	Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 163-163.	0.6	4
168	Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) â‰¥ 80 Years: Results of the French ATU Program.. Blood, 2009, 114, 1773-1773.	0.6	3
169	Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.. Blood, 2009, 114, 843-843.	0.6	13
170	Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program.. Blood, 2009, 114, 3820-3820.	0.6	0
171	Activity of elaeochytrin A from Ferula elaeochytris on leukemia cell lines. Phytochemistry, 2008, 69, 2979-2983.	1.4	40
172	Tumor dormancy and immunoescape. Apmis, 2008, 116, 685-694.	0.9	86
173	Dormant tumor cells as a therapeutic target?. Cancer Letters, 2008, 267, 10-17.	3.2	38
174	BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia, 2008, 22, 791-799.	3.3	41
175	220 ACETAMINOPHEN THERAPEUTIC MISADVENTURE: A PROSPECTIVE STUDY. Journal of Hepatology, 2008, 48, S91.	1.8	1
176	Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM. Blood, 2008, 112, 2672-2672.	0.6	2
177	Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program. Blood, 2008, 112, 2682-2682.	0.6	3
178	Long-Term Survival Analysis in Older Patients with AML Treated Intensively: Positive Impact of Idarubicin in a Cure Fraction Estimation Model.. Blood, 2008, 112, 960-960.	0.6	0
179	Core Binding Factor Acute Myeloid Leukemia of the Elderly Treated with Conventional Chemotherapy: A Collaborative Study of the French CBF AML Intergroup. Blood, 2008, 112, 553-553.	0.6	1
180	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe dâ€™Etude des Lymphomes de lâ€™Adulte. Journal of Clinical Oncology, 2007, 25, 787-792.	0.8	239

#	Article	IF	Citations
181	Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1. Cancer Research, 2007, 67, 4491-4498.	0.4	46
182	Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-Î³ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood, 2007, 110, 296-304.	0.6	546
183	MEK inhibitor: the MM magic bullet?. Blood, 2007, 110, 1402-1403.	0.6	4
184	Effect of priming with granulocyteâ€“macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia, 2007, 21, 453-461.	3.3	74
185	Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. Leukemia, 2007, 21, 2376-2377.	3.3	13
186	Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.. Blood, 2007, 110, 249-249.	0.6	41
187	Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.. Blood, 2007, 110, 1849-1849.	0.6	0
188	Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?. Expert Review of Vaccines, 2006, 5, 773-781.	2.0	10
189	In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice. Journal of Obstetrics and Gynaecology Research, 2006, 32, 449-453.	0.6	9
190	Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia, 2006, 20, 35-41.	3.3	149
191	Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia, 2006, 20, 965-970.	3.3	340
192	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia, 2006, 20, 2067-2070.	3.3	64
193	Methylation and myelodysplastic syndromes: When and where?. Leukemia Research, 2006, 30, 1327-1329.	0.4	5
194	RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.. Blood, 2006, 108, 2661-2661.	0.6	1
195	Clinical Relevance of Cardiac Iron Overload Estimated by MRI T2* in Regularly Transfused Low Risk MDS.. Blood, 2006, 108, 2666-2666.	0.6	4
196	An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients. Haematologica, 2006, 91, 1134-8.	1.7	16
197	NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood, 2005, 105, 2428-2435.	0.6	112
198	Multiple myeloma: all roads lead to cyclin D. Blood, 2005, 106, 1-2.	0.6	13

#	Article	IF	Citations
199	Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia, 2005, 19, 792-798.	3.3	108
200	Modelling a regional reorganization of cardiovascular surgery provision. Health and Place, 2005, 11, 283-292.	1.5	4
201	Induction of leukemia-specific CD8+ cytotoxic t cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-Î±. Molecular Therapy, 2005, 11, 950-959.	3.7	8
202	No Role for Chemoradiotherapy When Compared with Chemotherapy Alone in Elderly Patients with Localized Low Risk Aggressive Lymphoma: Final Results of the LNH93-4 GELA Study.. Blood, 2005, 106, 15-15.	0.6	16
203	Effect of Priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Younger Adults with Newly Diagnosed Acute Myeloid Leukemia (AML): A Trial by the Acute Leukemia French Association (ALFA) Group.. Blood, 2005, 106, 1862-1862.	0.6	0
204	Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple Myeloma. Leukemia and Lymphoma, 2004, 45, 2481-2484.	0.6	11
205	A case of refractory anemia with 17pâ^' syndrome following azathioprine treatment for heart transplantation. Leukemia, 2004, 18, 878-878.	3.3	8
206	Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia, 2004, 18, 1223-1230.	3.3	54
207	Efficient generation of antileukemic autologous T cells by short-term culture and ?-irradiation of myeloid leukemic cells. Cancer Immunology, Immunotherapy, 2004, 53, 793-8.	2.0	8
208	Short-term culture of myeloid leukemic cells allows efficient transduction by adenoviral vectors. Journal of Gene Medicine, 2004, 6, 751-759.	1.4	7
209	In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood, 2004, 104, 2124-2133.	0.6	156
210	Three new cases of non-Hodgkin lymphoma with t(9;14)(p13;q32). Cancer Genetics and Cytogenetics, 2003, 145, 65-69.	1.0	17
211	Chemotherapy increases transgene expression in leukemic cells. Journal of Gene Medicine, 2003, 5, 852-859.	1.4	1
212	Î³-Irradiation enhances transgene expression in leukemic cells. Gene Therapy, 2003, 10, 227-233.	2.3	18
213	SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia, 2003, 17, 1678-1679.	3.3	20
214	Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica, 2003, 88, 476-8.	1.7	24
215	Primary Central Nervous System Lymphoma in Immunocompetent Adults: Poor Results Mainly Associated with High Treatment Related Toxicities. Leukemia and Lymphoma, 2002, 43, 1819-1822.	0.6	7
216	Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma. Journal of Clinical Oncology, 2002, 20, 2472-2479.	0.8	194

#	Article	IF	Citations
217	p16INK4a immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. Blood, 2002, 99, 2620-2623.	0.6	27
218	TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma. Annales De GÃ©nÃ©tique, 2002, 45, 165-168.	0.4	2
219	Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. Bone Marrow Transplantation, 2002, 30, 229-234.	1.3	15
220	Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia, 2002, 16, 1637-1644.	3.3	45
221	Systemic injection of GM-CSF increases survival in a murine model of acute leukemia. Haematologica, 2002, 87, ELT13.	1.7	0
222	Pathologic and Clinical Features of 77 Hodgkin's Lymphoma Patients Treated in a Lymphoma Protocol (LNH87). American Journal of Surgical Pathology, 2001, 25, 297-306.	2.1	37
223	p16 INK4a andp15INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood, 2001, 98, 244-246.	0.6	77
224	Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients. Annals of Oncology, 2001, 12, 1749-1755.	0.6	14
225	Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype. Leukemia, 2001, 15, 1054-1059.	3.3	8
226	Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patients. The Hematology Journal, 2001, 2, 81-86.	2.0	5
227	Î³-Ray irradiation induces B7.1 expression in myeloid leukaemic cells. British Journal of Haematology, 2000, 108, 825-831.	1.2	57
228	Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Therapy, 2000, 7, 1312-1316.	2.3	42
229	Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Bone Marrow Transplantation, 2000, 25, 251-256.	1.3	43
230	Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Haematologica, 2000, 85, 502-7.	1.7	13
231	Transduction of Bone Marrow Cells by the AdZ.F(pK7) Modified Adenovirus Demonstrates Preferential Gene Transfer in Myeloma Cells. Human Gene Therapy, 1999, 10, 2709-2717.	1.4	42
232	P15^{INK4b}Gene Methylation and Myelodysplastic Syndromes. Leukemia and Lymphoma, 1999, 35, 437-443.	0.6	51
233	Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Gene Therapy, 1999, 6, 314-320.	2.3	57
234	Correspondence. Leukemia Research, 1999, 23, 415-416.	0.4	17

#	Article	IF	Citations
235	A NEW CASE OF THERAPY-RELATED ACUTE MYELOID LEUKAEMIA WITH t(8;16)(p11;p13). British Journal of Haematology, 1998, 100, 801-802.	1.2	2
236	Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression. Blood, 1998, 91, 2985-2990.	0.6	337
237	Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood, 1998, 91, 2985-90.	0.6	96
238	p16^{ink4a}Gene and Hematological Malignancies. Leukemia and Lymphoma, 1996, 22, 11-24.	0.6	26
239	Transfer of p16 inka /CDKN2 gene in leukaemic cell lines inhibits cell proliferation. British Journal of Haematology, 1996, 95, 291-298.	1.2	22
240	Analysis of p16 gene deletion and point mutation in breast carcinoma. British Journal of Cancer, 1995, 72, 351-353.	2.9	36
241	c-mplExpression in Hematologic Disorders. Leukemia and Lymphoma, 1995, 17, 19-26.	0.6	19
242	The Retinoblastoma Gene (RB-1) Status in Multiple Myeloma: A Report on 35 Cases. Leukemia and Lymphoma, 1995, 18, 497-503.	0.6	30
243	Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. British Journal of Haematology, 1994, 87, 61-67.	1.2	38
244	Over-expression of the MDM2gene is found in some cases of haematological malignancies. British Journal of Haematology, 1994, 88, 415-418.	1.2	60
245	MDM2 gene amplification in human breast cancer. European Journal of Cancer, 1994, 30, 982-984.	1.3	53
246	Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia, 1994, 8, 1342-9.	3.3	61
247	Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 1994, 8, 878-80.	3.3	12
248	Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature.. Journal of Clinical Oncology, 1993, 11, 2370-2379.	0.8	173
249	Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia, 1993, 7, 1888-90.	3.3	18
250	Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia, 1993, 7, 1071.	3.3	8